Can better approaches for suppressing gastric acid improve outcomes in patients with Helicobacter pylori infection?In this episode, Dr. Zhiqiang Song from the Department of Gastroenterology, Peking University Third Hospital, China, explains how potassium-competitive acid blockers (P-CABs)—therapeutics capable of more sustained gastric acid suppression compared to proton pump inhibitors (PPI)—may represent the future of standard care for H. pylori infection.A nationwide Phase III trial comparing P-CABs to PPIs in standard treatment regimens for H. pylori infection is the focus of an article by Dr. Song and collaborators published in the Chinese Medical Journal. The article is titled, “Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial.” Guest: Dr. Zhiqiang SongHost: John L Summary: We explore the potential benefits of using potassium-competitive acid blockers as an alternative to proton pump inhibitors in the standard eradication therapy for Helicobacter pylori.

Ver todos los episodios